Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Hikma’s profit was affected by the largest merger ever the comapny has made, and also investing more than double in R&D. The CEO said he is confident in future prospects http://bit.ly/2mrhi8n
"I am pleased and excited to be a part of the team for clinical development of NI-0401”, said Professor Sanyal. http://bit.ly/2mmre3a
It affects up to 132,000 people in the US and about 50,000 new cases are reported every year. http://bit.ly/2ncVQpl
Reducing loss with less clinical activity versus ongoing negotiations... I'm not sure
Hikma Pharmaceuticals said on Friday that its US subsidiary West-Ward Pharmaceuticals Corp. has launched two doses of generic Pfizer’s Pristiq (Desvenlafaxine Succinate) ER Tablets. http://bit.ly/2m9usaV
The IDMC has recommended that all three doses continue to be tested in the ongoing Phase 2b trial for BGS-649 http://bit.ly/2mgB1ee
Sanofi and AstraZeneca will together make Respiratory Syncytial Virus vaccine. AZ getting €120 million upfront and up to €495 more http://bit.ly/2lkPyXn
The company said that Rudi Pauwels will no longer be CEO, and will switch to the role of Chairman of a new Strategy Committee of the Board. After loss increasing to 50 million... what new strategy? Is this OK? http://bit.ly/2mwl451
Novo Nordisk’s vice president, head of North America leaves http://bit.ly/2lxwvVH
"...we believe that once-weekly semaglutide has the potential to improve the treatment for many type 2 patients in Japan..." http://bit.ly/2l76ssz
It should be there in four months. http://bit.ly/2mBxq81
“to accelerate the development of our diverse, oncology-focused pipeline and to support the working capital requirements of the Group to underpin further growth.” http://bit.ly/2lL6KEa
...potential benefit that Oxford BioMedica's immunotherapy treatment could give to patients with advanced colorectal cancer..." http://bit.ly/2l6fPDX
innovation is value, not squeezing more options from an old drug...he says.
CEO “We are delighted to commence trading on the London Stock Exchange" http://bit.ly/2mbhucS
yep
What was the interest for Pfizer here, there wasn't anything on the chat?
The company said on Wednesday it also cancels trading on the main London Stock Exchange market. http://bit.ly/2lKCTMT
Mereo orphan drug a part of the Adaptive Pathways http://bit.ly/2llSdN6
raised £100 million in its Initial Public Offering, with total market capitalisation at Admission to be £187 million. http://bit.ly/2ldIF6Z